参考文献/References:
[1]Ponikowski P,Voors AA,Anker SD,et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC)Developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J].Eur Heart J,2016,37(27):2129-2200. [2]Butler J,Fonarow GC,Zile MR,et al.Developing therapies for heart failure with preserved ejection fraction:current state and future directions[J].JACC Heart Fail,2014,2(2):97-112. [3]Chen YT,Wong LL,Liew OW,et al.Heart Failure with Reduced Ejection Fraction(HFrEF)and Preserved Ejection Fraction(HFpEF):The Diagnostic Value of Circulating MicroRNAs[J].Cells,2019,8(12):1651. [4]Rogers C,Bush N.Heart Failure:Pathophysiology,Diagnosis,Medical Treatment Guidelines,and Nursing Management[J].Nurs Clin North Am,2015,50(4):787-799. [5]Maggioni AP.Epidemiology of Heart Failure in Europe[J].Heart Fail Clin,2015,11(4):625-635. [6]Al-Omary MS,Davies AJ,Khan AA,et al.Heart Failure Hospitalisations in the Hunter New England Area Over 10 years.A Changing Trend[J].Heart Lung Circ,2017,26(6):627-630. [7]Shimokawa H,Miura M,Nochioka K,et al.Heart failure as a general pandemic in Asia[J].Eur J Heart Fail,2015,17(9):884-892. [8]Sun T,Li MY,Li PF,et al.MicroRNAs in Cardiac Autophagy:Small Molecules and Big Role[J].Cells,2018,7(8):104. [9]Zhang Y,Bauersachs J,Langer HF.Immune mechanisms in heart failure[J].Eur J Heart Fail,2017,19(11):1379-1389. [10]Mann DL.Innate immunity and the failing heart:the cytokine hypothesis revisited[J].Circ Res,2015,116(7):1254-1268. [11]Essandoh K,Li Y,Huo J,et al.MiRNA-Mediated Macrophage Polarization and its Potential Role in the Regulation of Inflammatory Response[J].Shock,2016,46(2):122-131. [12]Seok HY,Chen J,Kataoka M,et al.Loss of MicroRNA-155 protects the heart from pathological cardiac hypertrophy[J].Circ Res,2014,114(10):1585-1595. [13]Feng B,Chen S,Gordon AD,et al.miR-146a mediates inflammatory changes and fibrosis in the heart in diabetes[J].J Mol Cell Cardiol,2017(105):70-76. [14]Chistiakov DA,Orekhov AN,Bobryshev YV.The role of miR-126 in embryonic angiogenesis,adult vascular homeostasis,and vascular repair and its alterations in atherosclerotic disease[J].J Mol Cell Cardiol,2016(97):47-55. [15]Hartupee J,Mann DL.Neurohormonal activation in heart failure with reduced ejection fraction[J].Nat Rev Cardiol,2017,14(1):30-38. [16]Wong LL,Wee AS,Lim JY,et al.Natriuretic peptide receptor 3(NPR3)is regulated by microRNA-100[J].J Mol Cell Cardiol,2015(82):13-21. [17]Li D,Yang P,Xiong Q,et al.MicroRNA-125a/b-5p inhibits endothelin-1 expression in vascular endothelial cells[J].J Hypertens,2010,28(8):1646-1654. [18]Münzel T,Camici GG,Maack C,et al.Impact of Oxidative Stress on the Heart and Vasculature:Part 2 of a 3-Part Series[J].J Am Coll Cardiol,2017,70(2):212-229. [19]Marín-García J.Mitochondrial DNA repair:a novel therapeutic target for heart failure[J].Heart Fail Rev,2016,21(5):475-487. [20]Wang L,Yuan Y,Li J,et al.MicroRNA-1 aggravates cardiac oxidative stress by post-transcriptional modification of the antioxidant network[J].Cell Stress Chaperones,2015,20(3):411-420. [21]Magenta A,Dellambra E,Ciarapica R,et al.Oxidative stress,microRNAs and cytosolic calcium homeostasis[J].Cell Calcium,2016,60(3):207-217. [22]D’Agostino M,Martino F,Sileno S,et al.Circulating miR-200c is up-regulated in paediatric patients with familial hypercholesterolaemia and correlates with miR-33a/b levels:implication of a ZEB1-dependent mechanism[J].Clin Sci(Lond),2017,131(18):2397-2408. [23]Kuosmanen SM,Hartikainen J,Hippelainen M,et al.MicroRNA profiling of pericardial fluid samples from patients with heart failure[J].PLoS One,2015,10(3):e0119646. [24]González A,Schelbert EB,Díez J,et al.Myocardial Interstitial Fibrosis in Heart Failure:Biological and Translational Perspectives[J].J Am Coll Cardiol,2018,71(15):1696-1706. [25]Segura AM,Frazier OH,Buja LM.Fibrosis and heart failure[J].Heart Fail Rev,2014,19(2):173-185. [26]Dobaczewski M,Chen W,Frangogiannis NG.Transforming growth factor(TGF)-β signaling in cardiac remodeling[J].J Mol Cell Cardiol,2011,51(4):600-606. [27]Sygitowicz G,Maciejak-Jastrzebska A,Sitkiewicz D.MicroRNAs in the development of left ventricular remodeling and postmyocardial infarction heart failure[J].Pol Arch Intern Med,2020,130(1):59-65. [28]Hong Y,Cao H,Wang Q,et al.MiR-22 may Suppress Fibrogenesis by Targeting TGFβR I in Cardiac Fibroblasts[J].Cell Physiol Biochem,2016,40(6):1345-1353. [29]Deckx S,Heggermont W,Carai P,et al.Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation[J].Matrix Biol,2018(66):110-124. [30]Yan H,Ma F,Zhang Y,et al.miRNAs as biomarkers for diagnosis of heart failure:A systematic review and meta-analysis[J].Medicine(Baltimore),2017,96(22):e6825. [31]Magnussen C,Blankenberg S.Biomarkers for heart failure:small molecules with high clinical relevance[J].J Intern Med,2018,283(6):530-543. [32]Wang C,Yang H,Gao C.Potential biomarkers for heart failure[J].J Cell Physiol,2019,234(6):9467-9474. [33]Tijsen AJ,Creemers EE,Moerland PD,et al.MiR423-5p as a circulating biomarker for heart failure[J].Circ Res,2010,106(6):1035-1039. [34]Goren Y,Kushnir M,Zafrir B,et al.Serum levels of microRNAs in patients with heart failure[J].Eur J Heart Fail,2012,14(2):147-154. [35]Voellenkle C,van Rooij J,Cappuzzello C,et al.MicroRNA signatures in peripheral blood mononuclear cells of chronic heart failure patients[J].Physiol Genomics,2010,42(3):420-426. [36]Dickinson BA,Semus HM,Montgomery RL,et al.Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure[J].Eur J Heart Fail,2013,15(6):650-659. [37]Nair N,Kumar S,Gongora E,et al.Circulating miRNA as novel markers for diastolic dysfunction [J].Mol Cell Biochem,2013,376(1-2):33-40. [38]Wong LL,Armugam A,Sepramaniam S,et al.Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction[J].Eur J Heart Fail,2015,17(4):393-404. [39]Watson CJ,Gupta SK,O’Connell E,et al.MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure[J].Eur J Heart Fail,2015,17(4):405-415. [40]Vegter EL,van der Meer P,de Windt LJ,et al.MicroRNAs in heart failure:from biomarker to target for therapy[J].Eur J Heart Fail,2016,18(5):457-468. [41]Patrick DM,Montgomery RL,Qi X,et al.Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice[J].J Clin Invest,2010,120(11):3912-3916. [42]Wahlquist C,Jeong D,Rojas-Munoz A,et al.Inhibition of miR-25 improves cardiac contractility in the failing heart[J].Nature,2014,508(7497):531-535. [43]Song CL,Liu B,Diao HY,et al.The protective effect of microRNA-320 on left ventricular remodeling after myocardial ischemia-reperfusion injury in the rat model[J].Int J Mol Sci,2014,15(10):17442-17456. [44]Li W,Liu M,Zhao C,et al.MiR-1/133 attenuates cardiomyocyte apoptosis and electrical remodeling in mice with viral myocarditis[J].Cardiol J,2020,27(3):285-294. [45]Gill SL,O’Neill H,McCoy RJ,et al.Enhanced delivery of microRNA mimics to cardiomyocytes using ultrasound responsive microbubbles reverses hypertrophy in an in-vitro model[J].Technol Health Care,2014,22(1):37-51.
相似文献/References:
[1]郭俊林,张立.BNP对CRT后期疗效的临床评价[J].医学信息,2018,31(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
GUO Jun-lin,ZHANG li.Clinical Evaluation of BNP in Treatment of Late CRT[J].Medical Information,2018,31(04):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
[2]程 林.重组人脑利钠肽用于重症急性心肌炎伴
心力衰竭患者治疗的临床研究[J].医学信息,2018,31(08):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
CHENG Lin.Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure[J].Medical Information,2018,31(04):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
[3]胡丽君.螺内酯联合曲美他嗪治疗慢性心力衰竭的疗效分析[J].医学信息,2018,31(08):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
HU Li-jun.Efficacy of Spironolactone Combined with Trimetazidine in the Treatment of Chronic Heart Failure[J].Medical Information,2018,31(04):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
[4]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,31(04):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[5]平兰芝,黄小楼,胡天俊,等.CaMKⅡ在心血管疾病中的研究[J].医学信息,2022,35(10):59.[doi:10.3969/j.issn.1006-1959.2022.10.014]
PING Lan-zhi,HUANG Xiao-lou,HU Tian-jun,et al.Research on the Role of CaMKⅡ in Cardiovascular Diseases[J].Medical Information,2022,35(04):59.[doi:10.3969/j.issn.1006-1959.2022.10.014]
[6]刘革铭,马洪俊,刘 毅,等.心力衰竭的机制及诊疗的研究[J].医学信息,2022,35(10):91.[doi:10.3969/j.issn.1006-1959.2022.10.022]
LIU Ge-ming,MA Hong-jun,LIU Yi,et al.Mechanism, Diagnosis and Treatment of Heart Failure[J].Medical Information,2022,35(04):91.[doi:10.3969/j.issn.1006-1959.2022.10.022]
[7]黄光明,赵兴昌,符显昭.水中运动联合中药内治对糖尿病大鼠心肌细胞凋亡和心功能的影响[J].医学信息,2022,35(11):72.[doi:10.3969/j.issn.1006-1959.2022.11.020]
HUANG Guang-ming,ZHAO Xing-chang,FU Xian-zhao.Effects of Aquatic Therapeutic Exercise Combined with Traditional Chinese Medicine Internal Treatment on Cardiomyocyte Apoptosis and Cardiac Function in Diabetic Rats[J].Medical Information,2022,35(04):72.[doi:10.3969/j.issn.1006-1959.2022.11.020]
[8]何玲玲,程淑芬.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭疗效观察[J].医学信息,2018,31(13):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
HE Ling-ling,CHENG Shu-fen.Therapeutic Effect of Trimetazidine Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease with Heart Failure[J].Medical Information,2018,31(04):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
[9]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Medical Information,2018,31(04):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
[10]施国富,吴春阳,施亚明,等.血浆脑钠肽对射血分数保留心力衰竭患者的诊断价值研究[J].医学信息,2018,31(16):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
SHI Guo-fu,WU Chun-yang,SHI Ya-ming,et al.Diagnostic Value of Plasma Brain Natriuretic Peptide in Patients with Heart Failure Preserved by Ejection Fraction[J].Medical Information,2018,31(04):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]